Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

NCT01910389 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Stopped terminated by funding agency

Conditions

Heart Failure
Pulmonary Hypertension

Interventions

DRUG: Tadalafil
DRUG: Placebo for tadalafil

Sponsor

Carelon Research

Collaborators

[object Object]
[object Object]